SCHEMBL6438595

SCHEMBL6438595

COc1ccc2c(c1)COc1c-2cc(-c2cccs2)c2cc(OC)ccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.41
KMT2A Q03164 9/20 0.40
MAPT P10636 9/20 0.40
NPC1 O15118 7/20 0.40
RAB9A P51151 7/20 0.40
ALDH1A1 P00352 6/20 0.40
KDM4E B2RXH2 6/20 0.40
NFKB1 P19838 3/20 0.40
NFKB2 Q00653 3/20 0.40
RELA Q04206 3/20 0.40
GAA P10253 5/20 0.39
HSP90AA1 P07900 1/20 0.39
HSP90AB1 P08238 1/20 0.39
PRF1 P14222 1/20 0.39
MEN1 O00255 8/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
GABRA1 P14867 1/20 0.37
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA5 P31644 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4448131 0.80 PRF1 (0.37) MAPTRAB9AALDH1A1PRF1HPGD
SCHEMBL6439121 0.77 MAPT (0.39) MAOBKMT2AMAPTNPC1RAB9A
SCHEMBL6436081 0.74 KDM4E (0.38) KMT2AMAPTNPC1RAB9AALDH1A1
SCHEMBL6436077 0.73 RXRA (0.46) KMT2AMAPTNPC1RAB9AALDH1A1
SCHEMBL6436723 0.73 MPO (0.36) KMT2AMAPTNPC1RAB9AALDH1A1
SCHEMBL6440958 0.73 SMN1; SMN2 (0.38) KMT2AMAPTNPC1RAB9AALDH1A1
SCHEMBL6440956 0.73 SMN1; SMN2 (0.38) KMT2AMAPTNPC1RAB9AALDH1A1
SCHEMBL6440485 0.72 HSP90AA1 (0.43) KMT2AMAPTNPC1RAB9AALDH1A1
SCHEMBL6437588 0.70 KDM4E (0.46) MAPTNPC1RAB9AALDH1A1KDM4E
SCHEMBL26259491 0.70 MEN1 (0.47) MAOBKMT2AMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1453820-B1 SUBSTITUTED 6H-DIBENZO[C,H]CHROMENES AS ESTROGENIC AGENTS WYETH CORP (US) 2005-06-01 EP disclosed
US-6723747-B2 ESTROGEN RECEPTOR MODULATORS USEFUL IN TREATING OR INHIBITING CONDITIONS, DISORDERS, OR DISEASE STATES AT LEAST PARTIALLY MEDIATED BY ESTROGEN DEFICIENCY OR EXCESS, OR WHICH MAY BE TREATED OR INHIBITED THROUGH USE OF ESTROGENIC AGENT WYETH 2004-04-20 US disclosed
US-20030176491-A1 Substituted 6H-DiBenzo[c,h]chromenes as estrogenic agents WYETH 2003-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176491-A1 Substituted 6H-DiBenzo[c,h]chromenes as estrogenic agents ESR2, ESR1, ESRRA MAOB 2335/4885KMT2A 1060/4885MAPT 4552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.